EMA Application withdrawn: Durysta (bimatoprost) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

The EMA has withdrawn the marketing authorization application for Durysta (bimatoprost) submitted by AbbVie Deutschland GmbH & Co. KG for open-angle glaucoma an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• DURYSTA (BIMATOPROST)

Snippet

Status: Application withdrawn. Therapeutic area: Glaucoma, Open-Angle;Ocular Hypertension. MAH: AbbVie Deutschland GmbH & Co. KG